Mannkind Corp

NASDAQ: MNKD
$4.30
+$0.06 (+1.4%)
Closing price April 11, 2024
MannKind Corporation is a pioneering biopharmaceutical firm dedicated to creating inhaled therapeutic products for diabetes and rare lung diseases. Its flagship product, Afrezza, is an innovative inhaled insulin offering a new approach to glycemic control in adults. Additionally, MannKind is developing treatments for pulmonary arterial hypertension and other serious lung conditions. With strategic partnerships for global distribution and a commitment to advancing respiratory health, MannKind stands at the forefront of inhalation technology for medical treatments.

Cramer's Stock Picks at the Market Top
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Chris Lange
Published:

Short Sellers Shy Away From Big Biotech
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Chris Lange
Published:

Big Biotechs Scare Off Short Sellers
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Chris Lange
Published:

Short Sellers Can't Make Up Their Minds on Big Biotechs
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Chris Lange
Published:

Short Sellers Run for Cover From Major Biotechs
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Chris Lange
Published:

Major Biotechs Have Short Sellers on the Run
The May 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Chris Lange
Published:

Major Biotechs See More Targeted Short Sellers
The May 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks was mixed.
Chris Lange
Published:

Short Sellers Raise the Stakes in Major Biotechs
The April 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Chris Lange
Published:

Short Sellers Grow More Selective on Major Biotechs
The April 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Chris Lange
Published:

Big Biotechs Scare Off Short Sellers
The March 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks shrank.
Chris Lange
Published:

Major Biotechs Get Mixed Message on Short Interest
The March 13 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Chris Lange
Published:

Big Biotechs Have Short Sellers Confused
The February 28 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Chris Lange
Published:

Major Biotechs Have Short Sellers Confused
The February 14 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Chris Lange
Published:

Biotech Short Sellers Focus on a Couple Favorites
The January 31 data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Chris Lange
Published:

Short Sellers Wary on Major Biotechs
The January 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Chris Lange
Published: